Heart Metabolics Begins Phase IIb Perhexiline Study

Heart Metabolics launched an open-label Phase IIb study of perhexiline in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure with preserved left ventricular function.

The ascending dose study will evaluate the effect of perhexiline on changes from baseline oxygen consumption, following repeat dosing of perhexiline for 112 days. Changes in the six-minute walk test will serve as a secondary endpoint.

Heart Metabolics has begun dosing patients, and the study plans to enroll approximately 33 subjects at multiple U.S. sites.